#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
“What we’re seeing with cannabinoids and hepatic steatosis is a genuine metabolic effect that warrants clinical attention, particularly in older patients where fatty liver disease accelerates cognitive decline and cardiovascular risk. The mechanism appears to involve improved insulin sensitivity and reduced hepatic lipid accumulation, which means we may finally have a therapeutic option for patients who’ve exhausted conventional approaches. I’m now screening my Medicare patients with NAFLD for cannabis candidacy the same way I would for any evidence-based intervention.”
💊 Emerging preclinical evidence suggesting cannabinoids may have hepatoprotective properties against fatty liver disease is intriguing, but clinicians should approach these findings with appropriate caution given the limited human data, unclear optimal dosing, and variable cannabinoid composition across cannabis products. The study population of older Medicare beneficiaries is relevant to primary care, though observational designs cannot establish causation and may be confounded by lifestyle factors, comorbidities, or selection bias in cannabis use patterns. Furthermore, the legal and regulatory landscape remains fragmented, making it difficult to counsel patients on product quality, consistency, and potential drug interactions, particularly in older adults taking multiple medications. While these findings warrant further rigorous clinical trials, current evidence does not support recommending cannabis specifically for hepatic steatosis, and providers should continue emphasizing weight loss, alcohol reduction, and metabolic optimization as first-line interventions. For patients already using cannabis who have fatty
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: